The results of this analysis allowed defining 16 significantly mutated genes, including the four driver/founder genes KRAS, TP53, CDKN2A and SMAD4, other genes already known to be mutated in pancreatic cancer such as MLL3, TGFBR2, ARID1A and SF3B1 and unreported novel mutant genes, such as genes involved in chromatin modification (EPC1 and ARID2) and DNA damage repair (ZIM2, MAP2K4, NALCN, SLC16A4 and MAGE/A6) [13]. This evidence concerns the gene KMT2C and pancreatic neoplasm.